Trials / Unknown
UnknownNCT04934618
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
A Single-arm, Multicenter, Open-labeled, Phase II Study on the Efficacy and Safety of Carelizumab Combined With Irinotecan and Apatinib in the Second-line Treatment of Locally Advanced Unresectable, Recurrent or Metastatic Adenocarcinoma of Stomach and Gastroesophageal Junction
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the overall survival time (OS), objective remission rate（ORR）, progression-free survival time（PFS）, disease control rate（DCR）of Carelizumab combined with irinotecan and apatinib for the second-line treatment of locally advanced unresectable, recurrent or metastatic adenocarcinoma of stomach and gastroesophageal junction. At the same time, the safety and tolerance of the scheme were preliminarily evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carelizumab Combined With Irinotecan and Apatinib | Three-drug regimen was used in second-line treatment of Advanced gastric cancer |
Timeline
- Start date
- 2020-05-19
- Primary completion
- 2023-05-19
- Completion
- 2025-05-19
- First posted
- 2021-06-22
- Last updated
- 2021-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04934618. Inclusion in this directory is not an endorsement.